Use of antiperspirant in patients undergoing radiotherapy treatment for breast cancer.
DOI:
https://doi.org/10.35954/SM2022.41.1.2.e401Keywords:
Antiperspirants; Breast Cancer; Breast Neoplasms; Radiation Oncology; RadiotherapyAbstract
Patients who are diagnosed with breast cancer face multiple challenges and fears: from the diagnosis, the acceptance of the diagnosis and the beginning of the treatments, as well as the side effects that they entail, the most worrying for the patients being the possible anatomical alterations due to surgery, alopecia due to chemotherapy treatment, and radiodermatitis due to radiant treatment.
A systematic review was carried out in MedLine/Pubmed following the PRISMA 2020 criteria on the use of antiperspirant during radiant treatment in the axilla and its relationship or not with the increase in acute adverse effects.
Based on the analysis of the results of this search and with emphasis on: dosimetric aspects, psychological impact, treatment acceptance, feeling of well-being and adherence. We justify its use.
Received for review: February 2022
Accepted for publication: May 2022
Correspondence: Hospital de Cínicas Dr. Manuel Quintela. Avenida Italia S/N. C.P.11.600. Montevideo, Uruguay. Tel: (+598) 094470021.
E-mail Contact: ficolor@hotmail.com
Downloads
Metrics
References
(1) Barrios E, Garau M, Alonso R, Musetti C. V Atlas de Incidencia del Cáncer en el Uruguay. Periodo 2012-2016 [Internet]. Montevideo: Comisión Honoraria de Lucha Contra el Cáncer, 2020. Disponible en: https://www.comisioncancer.org.uy/Ocultas/V-Atlas-de-Incidencia-del-Cancer-en-el-Uruguay-Periodo-2012-2016-uc250 [Consulta: 15/01/2022]
(2) Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011; 378(9804): 1707-1716. https://doi.org/10.1016/S0140-6736(11)61629-2
(3) Joseph K, Vos LJ, Gabos Z, Pervez N, Chafe S, Tankel K, et al. Skin Toxicity in Early Breast Cancer Patients Treated with Field-In-Field Breast Intensity-Modulated Radiotherapy versus Helical Inverse Breast Intensity-Modulated Radiotherapy: Results of a Phase III Randomised Controlled Trial. Clinical oncology. Royal College of Radiologists. 2021; 33(1): 30-39. https://doi.org/10.1016/j.clon.2020.07.005
(4) Chan RJ, Webster J, Chung B, Marquart L, Ahmed M, Garantziotis S. Prevention and treatment of acute radiation-induced skin reactions: a systematic review and meta-analysis of randomized controlled trials. BMC Cancer 2014; 14:53. doi:10.1186/1471-2407-14-53.
(5) Wong RK, Bensadoun RJ, Boers-Doets CB, Bryce J, Chan A, Epstein JB, et al. Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer. 2013; 21(10):2933-2948. https://doi.org/10.1007/s00520-013-1896-2
(6) Baumann BC, Zeng C, Freedman GM, Verginadis II, MacArthur KM, Lin LL, et al. Avoiding antiperspirants during breast radiation therapy: Myth or sound advice?. Radiother Oncol: journal of the European Society for Therapeutic Radiol Oncol 2017; 124(2):204-207. https://doi.org/10.1016/j.radonc.2017.06.021
(7) Sharma N, Purkayastha A. Impact of Radiotherapy on Psychological, Financial, and Sexual Aspects in Postmastectomy Carcinoma Breast Patients: A Prospective Study and Management. Asia-Pacific J Oncol Nurs 2017; 4(1):69-76. https://doi.org/10.4103/2347-5625.199075
(8) Theofilou P, Panagiotaki H. A literature review to investigate the link between psychosocial characteristics and treatment adherence in cancer patients. Oncology Rev 2012; 6(1):e5. https://doi.org/10.4081/oncol.2012.e5
(9) Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow C D, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71. https://doi.org/10.1136/bmj.n71
(10) Graham PH, Graham JL. Use of deodorants during adjuvant breast radiotherapy: a survey of compliance with standard advice, impact on patients and a literature review on safety. J Med Imaging Radiat Oncol 2009; 53(6):569-573. doi:10.1111/j.1754-9485.2009.02125.x.
(11) Gee A, Moffitt D, Churn M, Errington R. A randomised controlled trial to test a non-metallic deodorant used during a course of radiotherapy. J Radiother Pract 2000; 1(4):205-212. doi:10.1017/S1460396999000321.
(12) Bennett C. An investigation into the use of a non-metallic deodorant during radiotherapy treatment: a randomised controlled trial. J Radiotherap Pract 2009; 8: 3-9. doi:10.1017/S146039690800647X.
(13) Théberge V, Harel F, Dagnault A. Use of axillary deodorant and effect on acute skin toxicity during radiotherapy for breast cancer: a prospective randomized non inferiority trial. Int J Radiat Oncol Biol Phys. 2009; 75(4):1048-1052. doi:10.1016/j.ijrobp.2008.12.046.
(14) Watson LC, Gies D, Thompson E, Thomas B. Randomized control trial: evaluating aluminum-based antiperspirant use, axilla skin toxicity, and reported quality of life in women receiving external beam radiotherapy for treatment of Stage 0, I, and II breast cancer. Int J Radiat Oncol Biol Phys 2012; 83(1):e29-e34. doi:10.1016/j.ijrobp.2011.12.006.
(15) Lewis L, Carson S, Bydder S, Athifa M, Williams AM, Bremner A. Evaluating the effects of aluminum-containing and non-aluminum containing deodorants on axillary skin toxicity during radiation therapy for breast cancer: a 3-armed randomized controlled trial. Int J Radiat Oncol Biol Phys 2014; 90(4):765-771. doi:10.1016/j.ijrobp.2014.06.054.
(16) Burch SE, Parker SA, Vann AM, Arazie JC. Measurement of 6-MV X-ray surface dose when topical agents are applied prior to external beam irradiation. Int J Radiat Oncol Biol Phys 1997; 38(2):447-451. doi:10.1016/s0360-3016(97)00095-3.
(17) Fackrell D, Kirby D, Sanghera P, Hartley A. The effect of silver sulfadiazine and zinc oxide creams on dose distribution during radiotherapy. J Radiother Prac Cambridge University Press 2015; 14(2):111-116. doi:10.1017/S1460396914000533.
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Federico Lorenzo, Marcelo Torres, Milexys Rivero, Angelina Patiño y Álvaro Notejane. authors retain their copyright and grant the journal the right of first publication of their work, which will be simultaneously subject to the Creative Commons Attribution 4.0 International License that allows sharing the work as long as the initial publication in this journal is indicated.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Until 2024 we use the Creative Commons Attribution/NonCommercial Attribution 4.0 International License https://creativecommons.org/licenses/by-nc/4.0/deed.es. Which states that: you are free to share, copy and redistribute the material in any medium or format, as well as to adapt, remix, transform and build upon the material. Under the following terms:
Attribution: you must give proper credit , provide a link to the license, and indicate if changes have been made . You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
NonCommercial: you may not use the material for commercial purposes.
As of 2025 authors retain their copyright and assign to the journal the right of first publication of their work, which shall simultaneously be subject to the license https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es that permits sharing, copying and redistribution of the material in any medium or format provided that initial publication in this journal is indicated. Adapt, remix, transform and build upon the material. If you remix, transform, or build from the material, you must distribute your contribution under the same license as the original and may not make use of the material for commercial purposes.
Under the following terms:
1. Attribution: you must give proper credit, provide a link to the license, and indicate whether changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
2. NonCommercial: you may not use the material for commercial purposes.
3. ShareAlike: if you remix, transform or build upon the material, you must distribute your contribution under the same license as the original.
PlumX Metrics
/
